Joshua L.  Smiley net worth and biography

Joshua Smiley Biography and Net Worth

Currently, Joshua L. Smiley is Treasurer, Director & Vice President at CoLucid Pharmaceuticals, Inc. Mr. Smiley is also on the board of Butler University and Eskenazi Health Foundation. In his past career he was Chief Financial Officer & Senior Vice President at Eli Lilly & Co. and Chief Financial Officer, Controller & SVP-Finance at Lilly Research Laboratories (a subsidiary of Eli Lilly & Co.). Joshua L. Smiley received an undergraduate degree from Harvard University.

What is Joshua L. Smiley's net worth?

The estimated net worth of Joshua L. Smiley is at least $15.97 million as of December 14th, 2023. Mr. Smiley owns 20,527 shares of Eli Lilly and Company stock worth more than $15,969,185 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Smiley may own. Learn More about Joshua L. Smiley's net worth.

How do I contact Joshua L. Smiley?

The corporate mailing address for Mr. Smiley and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Joshua L. Smiley's contact information.

Has Joshua L. Smiley been buying or selling shares of Eli Lilly and Company?

Joshua L. Smiley has not been actively trading shares of Eli Lilly and Company during the past quarter. Most recently, on Friday, October 25th, Joshua L. Smiley bought 929 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $107.59 per share, with a total value of $99,951.11. Following the completion of the transaction, the chief financial officer now directly owns 31,524 shares of the company's stock, valued at $3,391,667.16. Learn More on Joshua L. Smiley's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 34 times. They sold a total of 2,559,639 shares worth more than $21,797,395,907.59. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 1/31/2024.

Joshua L. Smiley Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2019Buy929$107.59$99,951.1131,524View SEC Filing Icon  
7/15/2019Buy185$108.47$20,066.9530,595View SEC Filing Icon  
6/5/2019Buy426$118.03$50,280.7830,410View SEC Filing Icon  
3/16/2018Sell3,000$79.20$237,600.0020,029View SEC Filing Icon  
See Full Table

Joshua L. Smiley Buying and Selling Activity at Eli Lilly and Company

This chart shows Joshua L Smiley's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $777.96
Low: $776.44
High: $793.67

50 Day Range

MA: $730.97
Low: $623.35
High: $792.28

2 Week Range

Now: $777.96
Low: $334.58
High: $800.78

Volume

3,185,016 shs

Average Volume

2,972,386 shs

Market Capitalization

$739.19 billion

P/E Ratio

134.13

Dividend Yield

0.67%

Beta

0.34